Home > Insider Trading > Filing (0001179110-14-012790)

Filing Details

Accession Number:: 0001179110-14-012790
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-08-12 21:49:03
Reporting Period:: 2014-08-08

Filing Date:: 2014-08-12
Accepted Time:: 2014-08-12 20:49:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1061027	Sunesis Pharmaceuticals Inc	SNSS	Pharmaceutical Preparations (2834)	943295878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1461466	Dayton Misfeldt	C/O Bay City Capital Llc 750 Battery Street, Suite 400 San Francisco CA 94111		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-08-08	662,378	$6.62	4,868,792	No	4	S	Indirect	See footnotes.
Common Stock	Disposition	2014-08-08	12,622	$6.62	92,780	No	4	S	Indirect	See footnotes.
Common Stock	Disposition	2014-08-11	31,009	$6.90	4,837,783	No	4	S	Indirect	See footnotes.
Common Stock	Disposition	2014-08-11	591	$6.90	92,189	No	4	S	Indirect	See footnotes.
Common Stock	Disposition	2014-08-12	36,406	$6.77	4,801,377	No	4	S	Indirect	See footnotes.
Common Stock	Disposition	2014-08-12	694	$6.77	91,495	No	4	S	Indirect	See footnotes.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes.
No	4	S	Indirect	See footnotes.
No	4	S	Indirect	See footnotes.
No	4	S	Indirect	See footnotes.
No	4	S	Indirect	See footnotes.
No	4	S	Indirect	See footnotes.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,515	Indirect	See footnotes.

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $6.71 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
The reporting person is a partner of Bay City Capital LLC, A Delaware limited liability company ("BCC"). BCC is the manager of Bay City Capital Management V LLC, a Delaware limited liablity company ("Management V"). Management V is the general partner of Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P.,a Delaware limited partnershp ("Co-Investment V") and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held. Mr. Misfeldt, BCC and Management V disclaim beneficial ownership with respect to the securities reported in this Form 4, except to the extent of their pecuniary interest therein.
These securities are held by Fund V.
These securities are held by Co-Investment V.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.87 to $6.94. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote five (5) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.925 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote six (6) of this Form 4.
These securities are held by BCC.